Voices
Aditi Hazra: Receipt of Guideline-Concordant Trimodality Therapy Is Not Consistent in Inflammatory Breast Cancer
Aditi Hazra/poster.bwh.harvard.edu

Aditi Hazra: Receipt of Guideline-Concordant Trimodality Therapy Is Not Consistent in Inflammatory Breast Cancer

Aditi Hazra, Assistant Director at VA COURAGE and Assistant Professor at Harvard Medical School, shared a post on LinkedIn:

“Our new inflammatory breast cancer study examines real-world treatment patterns and survival in 47,702 patients, showing that receipt of guideline-concordant trimodality therapy (TMT) is not consistent.

Where you are and how care is delivered shape outcomes.”

Title: Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer

Authors: José P. Leone, Julieta Leone, Pietro De Placido, Faina Nakhlis, Ilana Schlam, Kelly A. Hirko, Aditi Hazra, Elizabeth Troll, Jennifer R. Bellon, Carlos T. Vallejo, Nancy U. Lin, Sara M. Tolaney, Filipa Lynce

Read the Full Article in JAMA Network Open.

Aditi Hazra: Receipt of Guideline-Concordant Trimodality Therapy Is Not Consistent in Inflammatory Breast Cancer

Other articles about breast cancer on OncoDaily.

Aditi Hazra Breast Cancer cancer Carlos T Vallejo Elizabeth Troll Faina Nakhlis Filipa Lynce Ilana Schlam Jennifer R. Bellon Jose P Leone Julieta Leone Kelly A Hirko Nancy U Lin OncoDaily Oncology Pietro De Placido Sara M. Tolaney